EGFR and non-small cell lung carcinoma: Similarly, a randomized phase II trial of seribantumab in combination with erlotinib in patients with EGFR wild-NSCLC demonstrated progression-free survival benefits in patients with detectable HRG mRNA in the tumor [152].